Toby Talbot

733 total citations
7 papers, 21 citations indexed

About

Toby Talbot is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Toby Talbot has authored 7 papers receiving a total of 21 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 1 paper in Molecular Biology and 1 paper in Pulmonary and Respiratory Medicine. Recurrent topics in Toby Talbot's work include Cancer Immunotherapy and Biomarkers (3 papers), CAR-T cell therapy research (3 papers) and Cutaneous Melanoma Detection and Management (2 papers). Toby Talbot is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), CAR-T cell therapy research (3 papers) and Cutaneous Melanoma Detection and Management (2 papers). Toby Talbot collaborates with scholars based in United Kingdom, Switzerland and Italy. Toby Talbot's co-authors include Timothy M.M. Farley, Michael Rowe, Leonie Eastlake, Pippa Corrie, Anne S. Tsao, Raffaele Califano, Dariusz M. Kowalski, Saif Ahmad, Avinash Gupta and Andrew Furness and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Lung Cancer.

In The Last Decade

Toby Talbot

6 papers receiving 21 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Toby Talbot United Kingdom	3	18	9	5	3	2	7	21
Samuel Gamble United Kingdom	2	14 0.8×	8 0.9×	6 1.2×	4 1.3×		2	19
Edward H. Arbe-Barnes United Kingdom	4	27 1.5×	12 1.3×	8 1.6×	4 1.3×		6	48
Marcellus Augustine United Kingdom	1	13 0.7×	8 0.9×	5 1.0×	4 1.3×		2	16
Lisa D. Cleary United States	3	17 0.9×	11 1.2×	11 2.2×	4 1.3×		6	20
Kristin Kreider United States	3	23 1.3×	9 1.0×	5 1.0×			4	25
Elvire Roblin France	2	12 0.7×	8 0.9×	4 0.8×	5 1.7×	2 1.0×	5	23
Rômulo Leopoldo de Paula Costa Brazil	3	9 0.5×	6 0.7×	6 1.2×	3 1.0×		4	15
Moyar Ge United States	3	11 0.6×	14 1.6×	5 1.0×	5 1.7×		6	30
Soraya Kharboutli Germany	2	15 0.8×	9 1.0×	5 1.0×			4	18
D Darabantiu Romania	2	10 0.6×	12 1.3×	7 1.4×	2 0.7×		2	32

Countries citing papers authored by Toby Talbot

Since Specialization

Citations

This map shows the geographic impact of Toby Talbot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toby Talbot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toby Talbot more than expected).

Fields of papers citing papers by Toby Talbot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toby Talbot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toby Talbot. The network helps show where Toby Talbot may publish in the future.

Co-authorship network of co-authors of Toby Talbot

This figure shows the co-authorship network connecting the top 25 collaborators of Toby Talbot. A scholar is included among the top collaborators of Toby Talbot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toby Talbot. Toby Talbot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Tsao, Anne S., et al.. (2026). Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. Journal of Clinical Oncology. 44(9). 742–749.

2.

Furness, Andrew, Lalit Pallan, Leila Khoja, et al.. (2024). 1129P Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM). Annals of Oncology. 35. S742–S743. 2 indexed citations

3.

Escriu, Carles, Riyaz Shah, Samantha Cox, et al.. (2024). Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis. Therapeutic Advances in Medical Oncology. 16. 12717693–12717693. 1 indexed citations

4.

Edner, Natalie M., Elisavet Ntavli, Lina Petersone, et al.. (2023). Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood. PubMed. 3(1). ltad001–ltad001. 4 indexed citations

5.

Rowe, Michael, et al.. (2021). A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab. Journal of Immunotherapy. 44(4). 175–178. 8 indexed citations

6.

Talbot, Toby, Adam Dangoor, Riyaz Shah, et al.. (2017). The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study. Lung Cancer. 113. 115–120. 2 indexed citations

7.

Ahmad, Saif, Wendi Qian, Sarah Ellis, et al.. (2013). Ipilimumab in the real world: The U.K. expanded access programme (EAP) experience in advanced melanoma.. Journal of Clinical Oncology. 31(15_suppl). 3018–3018. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact